Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
76.35
+0.55 (+0.73%)
Official Closing Price
Updated: 4:15 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
November 16, 2023
The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small
Via
Benzinga
Exposures
Product Safety
AstraZeneca's Flagship Cancer Drug Imfinzi Fails On Main Goal In Lung Cancer Trial When Combined With Chemoradiotherapy
November 14, 2023
AstraZeneca Plc (NASDAQ: AZN) said its PACIFIC
Via
Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology
November 14, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Royal Rule: Buy These 3 Dividend Aristocrats on Every. Single. Dip.
November 13, 2023
Choosing dividend aristocrats to buy becomes easy when you elect to buy the royalty of income-generating stocks.
Via
InvestorPlace
Investigating AstraZeneca's Standing In Pharmaceuticals Industry Compared To Competitors
November 13, 2023
Via
Benzinga
Price Over Earnings Overview: AstraZeneca
November 06, 2023
Via
Benzinga
Comparative Study: AstraZeneca And Industry Competitors In Pharmaceuticals Industry
October 30, 2023
Via
Benzinga
Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal
November 11, 2023
Eccogene, a Shanghai-Boston biotech, out-licensed global rights (ex-China) for its novel small molecule GLP-1 agonist to AstraZeneca in a $2 billion blockbuster deal. Eccogene will receive $185 million...
Via
Talk Markets
The 7 Next Trillion Dollar Companies to Invest in to Become a Millionaire
November 10, 2023
These are the next trillion-dollar companies to buy as they represent strong business fundamentals with robust cash flow upside potential.
Via
InvestorPlace
AstraZeneca Plc (AZN) Q3 2023 Earnings Call Transcript
November 09, 2023
AZN earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Auto Trader & AstraZeneca Help FTSE Reverse Early Losses
November 09, 2023
As the day progressed, the initial downturn was reversed, and the blue-chip index managed to secure gains just shy of 1%.
Via
Talk Markets
AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs
November 09, 2023
The company is licensing a new GLP-1 drug in the hopes of taking on Novo and Lilly.
Via
Investor's Business Daily
AstraZeneca Joins Anti-Obesity Race Dominated By Eli Lilly And Novo Nordisk, Reports Mixed Q3 Earnings
November 09, 2023
AstraZeneca Plc (NASDAQ: AZN) has reported Q3 FY23 core EPS of $1.73, u
Via
Benzinga
Wall Street To Snap Longest Winning Streak Since 2021 Today? Earnings, Bond Yields In Focus Ahead Of Powell's Speech
November 09, 2023
The stock market’s momentum appears to be waning, and futures suggest a mixed opening for Thursday. Earnings reports have generally been positive, with companies like Walt Disney Co.
Via
Benzinga
Earnings Review: AstraZeneca Increases Profit Outlook, Reports 17% EPS Growth
November 09, 2023
AstraZeneca reported an EPS of $1.73 for Q3 2023 and $5.8 for 9M 2023.
Via
Talk Markets
IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial
November 09, 2023
From
AstraZeneca
Via
Business Wire
AstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivity
November 08, 2023
From
AstraZeneca
Via
Business Wire
BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake
November 07, 2023
The company's recently FDA-approved gene therapy is struggling to gain traction.
Via
Investor's Business Daily
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Impact of Exclusive Drug-Delivery Solution on GLP-1 Drugs
November 03, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial
November 03, 2023
From
AstraZeneca
Via
Business Wire
7 Evergreen Stocks for Long-term Wealth Generation
November 03, 2023
These are the stocks to buy for long-term wealth as they represent companies that will continue to grow and boost shareholder returns.
Via
InvestorPlace
Why Is Cancer Player Cellectis Stock Trading Over 100% Higher Today?
November 01, 2023
Cellectis SA (NASDAQ: CLLS) shares are trading higher after the company
Via
Benzinga
Why Is Cellectis (CLLS) Stock Up 175% Today?
November 01, 2023
Cellectis stock is taking off on Wednesday as investors in CLLS react to a massive $245 million investment from AstraZeneca.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
November 01, 2023
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today!
Via
InvestorPlace
Can Diabetes, Weight-Loss Drugs Get Even Better?
October 30, 2023
Via
Investor Brand Network
Can Diabetes, Weight-Loss Drugs Get Even Better?
October 30, 2023
EQNX::TICKER_START (NASDAQ:LEXX,NYSE:NVO:NYSE:PFE,NYSE:MRK,NASDAQ:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
3 No-Brainer Stocks to Buy for Under $100 Right Now
October 28, 2023
A couple of these stocks might not be available for under $100 for too much longer.
Via
The Motley Fool
Why Is LumiraDx (LMDX) Stock Down 35% Today?
October 24, 2023
LumiraDx stock is falling on Tuesday as shares of LMDX stock give up some of the gains they saw on Monday after announcing a partnership.
Via
InvestorPlace
US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal)
October 24, 2023
From
AstraZeneca
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
October 23, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.